Abstract
The central role of plasma cholesterol in atherogenesis has been amply demonstrated (1). It is also well established that hyperlipidemia is an important risk factor for coronary heart disease (CHD). In addition there is considerable evidence in experimental animals (1,2) and in man (1,3–5) that lowering of plasma lipids will reduce the cardiovascular complications of atherosclerosis and promote regression of the lesions. The physician is thus justified to make an all out effort to reduce elevated plasma lipid levels in the hope of preventing, arresting, or reverting the atherosclerotic process. This is especially important when a diagnosis of hereditary hyperlipidemia is established since in many instances, as in familial hypercholesterolemia (FH), the affected individuals may be at risk of developing cardiovascular complications at an early age. In other situations (lipoprotein lipase deficiency for instance), the physician might want to lower the plasma lipids to prevent an acute attack of pancreatitis or to bring about a regression of unsightly xanthomatous skin lesions. To be effective, any approach to the treatment of familial hyperlipidemias must be rational and systematic. I would like to review here the major steps to be taken in such a therapeutic program (6,7).
Keywords
- Plasma Cholesterol
- Familial Hypercholesterolemia
- Familial Hypercholesterolemia
- Plasma Lipid Level
- Intermediate Density Lipoprotein
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
J. Davignon, Current views on the etiology and pathogenesis of atherosclerosis. In: “Hypertension: Physiopathology and Treatment”, J. Genest, E. Koiw and O. Küchel, eds., McGraw-Hill Book Co., New York (1977).
M. L. Armstrong, Evidence of regression of atherosclerosis in primates and man. Postgrad. Med. J. 52: 456 (1976).
C. R. Ost, and S. Stenson, Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid. Scand. J. Clin. Lab. Invest. Suppl. 99: 241 (1967).
L. L. Basta, C. Williams, J. M. Kioschos, and A. Spector, Regression of atherosclerotic stenosing lesions of the renal arteries and spontaneous cure of systemic hypertension through control of hyperlipidemia. Amer. J. Med. 86: 139 (1976).
R. Barndt Jr, D. H. Blankenhorn, D. W. Crawford, and S. H. Brooks, Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann. Int. Med. 86: 139 (1977).
J. Davignon, The hyperlipoproteinemias. In: “Current Therapy”, H.F. Conn, ed., W. B. Saunders, Philadelphia (1978).
J. Davignon, and S. Lussier-Cacan, Approche systematique au traitement des hyperlipidemies hereditaires. Rev. Med. Liege 35: 286 (1980).
A. Gattereau, E„ Elie, W. Figareau, and J. Davignon, Etude preliminaire des caracteristiques du lipidogramme liees a la presence de l’anneau corneen chez un groupe d’Haitiens. Union Med. Can. 104: 1359 (1975).
R. H. Rosenman, R. J. Brand, R. I. Sholtz, and C.D. Jenkins, Relation of corneal arcus to cardiovascular risk factors and the incidence of coronary heart disease. New Engl. J. Med. 291: 1322 (1974).
Ph. Douste-Blazy, Y.L. Marcel, L. Cohen, J.M. Giroux, and J. Davignon, Increased frequency of apo E-ND phenotype and hyperapobetalipoproteinemia in normolipidemic subjects with xanthelasmas of the eyelids. Ann. Int. Med. 96:164 (1982)
A. Watanabe, A. Yoshimura, T. Wakagushi, R. Tatami, K. Veda, R. Veda, T. Haba, T. Kametani, J. Koizumi, S. Ito, W. Ohta, S. Miyamoto, H. Mabuchi, and R. Takeda, Serum lipids, lipoprotein lipids and coronary heart disease in patients with xanthelasma palpebrarum. Atherosclerosis 38: 283 (1981).
J. Davignon, Les medicaments dans le traitement des hyperlipidemies - necessites et limites. In: “Symposium sur le Probucol”, J. Beaumont and B. Jacotot, eds., Excerpta Medica, Amsterdam (1981).
J. Davignon, S. Lussier-Cacan, A. Gattereau, P. P. Moll, and C. F. Sing, Studies of a large French-Canadian kindred with two forms of hyperlipoproteinemia. In: “Atherosclerosis V”, A. M. Gotto Jr., L. C. Smith and B. Allen, eds., Springer-Verlag, New York (1980).
D. S. Fredrickson, J. L. Goldstein, and M. S. Brown, The familial hyperlipoproteinemia. In: “The metabolic basis of inherited disease”, J. B. Stanbury, J. B. Wyngaarden and D. S. Fredrickson, eds., McGraw-Hill, New York (1978).
P. Elias, and L. A. Goldsmith, Intertriginous xanthomata in type 2 hyperbetalipoproteinemia. Arch. Dermatol. 107: 761 (1973).
D.S. Fredrickson, R.I. Levy, and R. S, Lees, Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. New Engl. J. Med. 276:94,148,215,273, (1967).
J. L. Goldstein, W.R. Hazzard, H.G. Schrott, E.L. Bierman, and A.G. Motulsky, Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52: 1544 (1973).
J. D. Brunzell, H.G. Schrott, A.G. Motulsky, and E.L. Bierman, Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 25: 313 (1976).
C. J. Glueck, R.W. Fallat, R. Millet, and P. M. Steiner, Familial hyperalphalipoproteinemia: studies in eighteen kindreds. Metabolism 24: 1243 (1975).
F. T. Hatch, and R. S. Lees, Practical methods for plasma lipoprotein analysis. _In: “Advances in Lipid Research”, R. Paoletti and D. Kritchevsky, eds., Academic Press, New York (1968).
J. Davignon, and M. Langelier, Electrophorese et ultracentrifugation combinees dans le diagnostic des hyperlipidemies primaires. Union Med. Can. 100: 2120 (1971).
D.S. Fredrickson, J. Morganroth, and R. I. Levy, Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann. Int. Med. 82:150(1975).
B. H. Masket, R.I. Levy, and D. S. Fredrickson, The use of polyacrylamide gel electrophoresis in differentiating type III hyperlipoproteinemia. J. Lab. Clin. Med. 81: 794 (1973).
M. D. Curry,.W.J. McConathy, P. Alaupovic, J. H. Ledford, and M. Popovic, Determination of human lipoprotein E by electroimmunoassay. Biochim. Biophys. Acta 439:413 (1976).
G. Utermann, M. Hees, and A. Steinmetz, Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature 269: 604 (1977).
J. L. Breslow, and V. I. Zannis, Biochemical and genetic studies of human apolipoprotein E. In: “Drugs affecting lipid metabolism”, R. Fumagalli, K. Tritchevsky and R. Paoletti, eds., Elsevier North-Holland, Amsterdam (1980).
J. C. La Rosa, R. I. Levy, P. Herbert, S. E. Lux, and D. S. Fredrickson, A specific apoprotein cofactor for lipoprotein lipase. Biochem. Biophys Res. Communic. 41: 57 (1970).
W. C. Breckenridge, J. A. Little, G. Steiner, A. Chow, A. and M. Poapst, Hypertriglyceridemia associated with deficiency of apolipoprotein CI I. New Engl. J. Med. 298: 1265 (1978).
W. C. Breckenridge, D. Cox, and J. A. Little, Apolipiprotein CI I deficiency. In: Atherosclerosis V. A. M. Gotto Jr., L. C. Smith and B. Allen eds., Springer-Verlag, New York (1980).
J. A. Little, D. Cox, D., W. C. Breckenridge, and V. M. McGuire, Introduction to deficiencies in apolipoproteins CII and EIII with some associated clinical findings. In: Atherosclerosis V. A. M. Gotto Jr., L. C. Smith and B. Allen eds., Springer-Verlag, New York (1980).
P. O. Kwiterovich, Jr., P. S. Bachorik, H. H. Smith, V. A. McKusick, W. E. Connor, B. Teng, and A. D. Sniderman, Hyperapobetalipoproteinaemia in two families with xanthomas and phytosterolaemia. Lancet 1:466 (1981).
A. D. Sniderman, S. Shapiro, D. Marpole, B. Skinner, B., B. Teng, and P. O. Kwiterovich, Jr., Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density (3) lipoproteins). Proc. Natl. Acad. Sci. USA, 77:604 (1980).
A. K. Bhattacharyya, and W. E. Connor, g-sitosterolemia and xanthomatosis, a newly described lipid storage disease in two sisters. J. Clin. Invest. 53: 1033 (1974).
C. J. Glueck, P. Gartside, P., R. W. Fallat, J. Sielski, and P. M. Steiner, Longevity syndromes: Familial hypobeta and familial hyperalphalipoproteinemia. J. Lab. Clin. Med. 88:941 (1976).
J. L. De Gennes, G. Turpin, and J. Truffert, Dgpistage et identification des hyperlipidemies idiopathique. Un nouveau test. Comparaison des concentrations des lipides circulants à la 8e et à la 12e heure de jeûne. Nouv. Presse Med. 1:1629 (1972).
J. Morganroth, R. I. Levy, A. E. McMahon, and A. J. Gotto, Jr, Pseudohomozygous type II hyperlipoproteinemia. J. Pediat. 85: 639 (1974).
A. K. Bhattacharyya, and W. E. Connor, Familial diseases with storage of sterols other than cholesterol (cerebro-tendinous xanthomatosis and β-sitosterolemia and xanthomatosis). In: “The metabolic basis of inherited disease”, J.B. Stanbury, J.B. Wyngaarden and D.S. Fredrickson, eds., McGraw-Hill, New York (1978).
R. H. Grimm Jr, A. S. Leon, D. B. Hunninghake, K. Lenz, P. Hannan, and H. Blackburn, Effects of thiazine diuretics of plasma lipids and lipoproteins in mildly hypertensive patients. Ann. Int. Med. 94: 7 (1981).
R. H. Grimm Jr, A. S. Leon, D. B. Hunninghake, K. Lenz, P. Hannan, and H. Blackburn, Effects of thiazine diuretics of plasma lipids and lipoproteins in mildly hypertensive patients. Ann. Int. Med. 94:7 (1981).
W. E. Connor, and W. L. Connor, Dietary treatment of hyperlipo-proteinemia. In: “Hyperlipidemia, diagnosis and therapy”, Grune and Stratton, New York (1977).
J. Davignon, S. Lussier-Cacan, and J. Ph. Wolf, Le traitement de l’atherogenèse, les facteurs de risque, en particulier les hyperlipidemies. In: “L’athérogenèse”, J. Hugues, ed., Masson, Paris ( 1979 ].
J. Davignon, N. Leboeuf, and S. Lussier-Cacan, Aspects nutritionnels du traitement des hyperlipidémies et de l’atherosclérose. Union Méd. Can. 109:656 (1980).
A. J. Vergroesen, Physiological effects of dietary linoleic acid. Nutr. Rev. 35: 1 (1977).
J. Slack, Inheritance of familial hypercholesterolemia. Ather. Rev. 5: 35 (1979).
A. J. Palmer, and R. Blacket, Regression of xanthomata of the eyelids with modified fat diet. Lancet 1: 66 (1972).
D. B, Hunninghake, and J. L. Probstfield, Drug treatment of hyperlipoproteinemia. In.: “Hyperlipidemia, diagnosis and therapy”, B.M. Rifkind and R.I. Levy, eds., Grune et Stratton, New York (1977).
S. M. Grundy, Treatment of hypercholesterolemia by interference with bile acid metabolism. Arch. Int. Med. 130: 638 (1972).
J. Davignon, F. Aubry, C. Noel, Y. Lapierre, and M. Lafortune, Heterogeneity of familial hyperlipoproteinemia type II on the basis of fasting plasma triglyceride/ cholesterol ratio and plasma cholesterol response to chlorophenoyisobutyrate. Rev. Can. Biol. 30: 307 (1971).
J. Davignon, A. Sniderman, M. N. Cayen, W. T. Robinson, M. Kraml, E. Reichel, and S. Lussier-Cacan, Sensitivity and resistance to the cholesterol-lowering effect of clofibrate - Pharmacokinetic studies, plasma apolipoprotein B levels and therapeutic implications. In: “Drugs affecting lipid metabolism”, R. Fumagalli, D. Kritchevsky and R. Paoletti, eds., Elsevier/North Holland, Amsterdam (1980).
D. B. Hunninghake, Drug treatment of type II hyperlipoproteinemia - Effects on plasma lipid and lipoprotein levels. In: “Atherosclerosis V”, A. M.. Gotto Jr., L. C. Smith and B Allen, eds., Springer-Verlag, New York (1980).
The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. J. Amer. Med. Assoc. 231: 360 (1975).
R. S. Lees, Clofibrate and atherosclerosis. New Engl. J. Med. 300: 491 (1979).
R. B. W. Smith, and I. A. M. Prior, Oral contraceptive opposition to hypocholesterolaemic action of clofibrate. Lancet 1: 750 (1968).
T. Langer, and R. I. Levy, Acute muscular syndrome associated with administration of clofibrate. New Engl. J. Med. 279: 856 (1968).
J. K. Reddy, D.L. Azarnoff, and C. E. Hignite, Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carninogens. Nature 283: 397 (1980).
M. F. Oliver, J. A. Heady, J. N. Morris, and Cooper, J, A cooperative trial in the primary prevention of ischaemic heat disease using clofibrate - Report from the committee of principal investigators. Brit. Heart J. 40:1069 (1978).
J. LeLorier, S. Dubreui1-Quidoz, S. Lussier-Cacan, Y. S. Huang, and J. Davignon, Diet and probucol in lowering cholesterol concentrations. Arch. Int. Med. 137: 1429 (1977).
M. Enjalbert, S. Lussier-Cacan, S. Dubreuil-Quidoz, J. LeLorier, and J. Davignon, Usefulness of probucol in treating primary hypercholesterolemia. Can. Med. Assoc. J. 123: 754 (1980).
T. A. Miettinen, Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemia. Atherosclerosis 15: 163 (1972).
P. J. Nestel, and T. Billington, Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis 38: 203 (1981).
Y. S. Huang, M.Asselin, C. Gianoulakis, M. Lis, M. Chretien, and J. Davignon, Liver lipid metabolism and effect of cholesterol-lowering agents in the hyperlipidemia induced in rats by implantation of the pituitary derived MtT-F4 tumor. Can. J. Physiolo Pharmacol. 58:767 (1979).
L. A. Carlson, and L. Oro, Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis 18: 1 (1973).
L. A. Simons, and N. B. Myant, The effect of D-thyroxine on the metabolism of cholesterol in familial hyperbetalipo- proteinaemia. Atherosclerosis 19: 103 (1974).
D. M. Krikler, D. Lefevre, and B. Lewis, Dextrothyroxine with propranolol in treatment of hypercholesterolaemia. Lancet 1:934 (1971).
A. M. Lees, H. Y. I. Mok, R. S. Lees, M. A. McCluskey, and S. M. Grundy, Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. Atherosclerosis 28: 325 (1977).
P. Samuel, C. M. Holtzman, and J. Goldstein, Long term reduction of serum cholesterol levels of patients with atherosclerosis by small doses of neomycin. Circulation 35: 938 (1967).
P. J. Barter, W. E. Connor, A. A. Spector, M. Armstrong, L. Sonja, B. S. Connor, and M. A. Newman, Lowering of serum cholesterol and triglycerides by para-aminosalicylic acid in hyperlipoproteinemia. Ann. Int. Med. 81: 619 (1974).
C. J. Glueck, V. W. Brown, R. I. Levy, H. Greten, and D. S. Fredrickson, Amelioration of hypertriglyceridemia by progestational drugs in familial type V hyperlipoproteinemia. Lancet 1: 1290 (1969).
C. J. Glueck, Effects of oxandrolone on plasma triglycerides and postheparin lipolytic activity in patients with type III, IV and V familial hyperlipoproteinemia. Metabolism 20: 691 (1971).
H. Buchwald, R. Moore, and R. L. Varco, Surgical treatment of hyperlipidemia. Circulation 49, Suppl. 1: 1 (1974).
T. E. Starzl, C. W. Putnam, and L. J. Koep, Portacaval shunt and hyperlipidemia. Arch. Surg. 113: 71 (1978).
T. A. Miettinen, Comparison of cholestyramine, ileal-bypass and portacaval shunt in the treatment of familial hypercholesterolemia. In: “Atherosclerosis V”. A. M. Gotto Jr., L. C. Smith and B. Allen, eds., Springer-Verlag, New York (1980).
M. Servelle, Ligation of the chyliferous vessels in the treatment of arteriosclerosis. In: “International Conference on Atherosclerosis”, L. A. Carlson, R. Paoletti, C. R. Sirtori and G. Weber, eds., Raven Press, New York (1978).
G. R. Thompson, R.Lowenthal, and N. B. Myant, Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1:1208 (1975).
P. J. Lupien, S. Moorjani, and J. Awad, A new approach to the management of familial hypercholesterolaemia: removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet 1: 1261 (1976).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Plenum Press, New York
About this chapter
Cite this chapter
Davignon, J. (1985). Diagnosis and Treatment of Hyperlipidemias. In: Halpern, M.J. (eds) Lipid Metabolism and Its Pathology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2445-4_23
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2445-4_23
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9486-3
Online ISBN: 978-1-4613-2445-4
eBook Packages: Springer Book Archive